Commentary: PBMs take the lead to prevent opioid misuse | Sponsored by the Pharmaceutical Care Management Association: America's Opioid Epidemic: A Role for Technology | HHS urges pharmaceutical firms to voluntarily lower drug prices, sources say
June 12, 2018
PCMA SmartBrief
News for the PBM Industry
Featured Story
Commentary: PBMs take the lead to prevent opioid misuse
Pharmacy benefit managers have a long history of promoting appropriate medication use and are taking the lead in advocating policies to prevent opioid misuse, such as requiring electronic prescribing of controlled substances and mandating Medicare Part D pharmacy lock-in programs for at-risk subscribers, writes John Jones, who teaches pharmacy law and ethics.
Capitol Weekly (Sacramento, Calif.) (6/11) 
LinkedIn Twitter Facebook Google+ Email
Legislative & Regulatory News
HHS urges pharmaceutical firms to voluntarily lower drug prices, sources say
HHS urges pharmaceutical firms to voluntarily lower drug prices, sources say
(Joe Raedle/Getty Images)
HHS officials have been meeting with drugmakers to encourage them to voluntarily cut their drug prices, but it remains unclear whether any of those firms agreed to do so, sources say. President Donald Trump said late last month that he expects pharmaceutical firms to announce "massive drops in prices" in two weeks, a time period that ends this week, and an HHS spokesperson on Monday said the agency is working with pharmaceutical firms, insurers, health care providers and other industry stakeholders to lower prescription drug prices.
The Hill (6/11) 
LinkedIn Twitter Facebook Google+ Email
Guidance details how states can use Medicaid funds to fight opioid crisis
The CMS released guidance on how states can use federal Medicaid funds to support health information technology efforts including telemedicine programs, EHR systems and prescription monitoring tools to combat the opioid abuse crisis.
The Hill (6/11),  Healthcare Finance (6/11),  MedPage Today (free registration) (6/11) 
LinkedIn Twitter Facebook Google+ Email
Drug Industry Spotlight
Lupin to focus on biosimilars, complex generics, specialty medicines
Drugmaker Lupin is shifting its focus to complex generics, biosimilars and specialty medicines to fuel growth, while continuing to expand its generics business, the company said during an investor presentation. Lupin's first biosimilar was filed in Japan, and a filing in Europe is expected soon.
BioSpectrum Asia (6/11) 
LinkedIn Twitter Facebook Google+ Email
Other News
You have to trust in something -- your gut, destiny, life, karma, whatever. Because believing that the dots will connect down the road will give you the confidence to follow your heart even when it leads you off the well-worn path, and that will make all the difference.
Steve Jobs,
LinkedIn Twitter Facebook Google+ Email
Learn more about PCMA:
Upcoming PCMA Events | PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information